CRISPR-based gene editing shows promise in treating rare form of blindness

FHS
May 6, 2024
6:43 pm

About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine.

Antidepressant fluoxetine found ineffective for early COVID-19 treatment

Findings reveal fluoxetine’s weak antiviral effects in COVID-19, with no significant benefits in symptom resolution compared to other antiviral treatments.

January 22, 2025

UCLA study finds no significant benefit of paxlovid for vaccinated older adults

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

February 22, 2025

Organ aging measured by blood test may help predict age-related diseases

Our organs age at different rates, and a blood test determining how much they’ve each aged could predict the risk of conditions like lung cancer

February 26, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.